New Approach to T2DM: Do DPP4 inhibitors like linagliptin still fit in?

The aim of this webinar is to provide updates on how Linagliptin simplifies type 2 diabetes management and how it stands out versus other dipeptidyl peptidase-4 (DPP4) inhibitors. It will discuss the clinical data and real-world evidence supporting its proven consistent efficacy and safety across a broad range of patients. Furthermore, the different renal excretion rate of DPP4i will be discussed and how the lowest renal excretion rate of Linagliptin truly offers no dose adjustment for its patients.

Estimated time of Completion: 35 mins

CPD Points: 1 Point

PRC Program No: PROG-2021-19676